லெ செவாலியர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லெ செவாலியர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லெ செவாலியர் Today - Breaking & Trending Today

Destination Mercury by Andrew Liptak : Clarkesworld Magazine - Science Fiction & Fantasy


Science Fiction & Fantasy
 
by Andrew Liptak
There is no better example of how science fiction’s tendency to try and imagine a plausible future is like throwing a dart at a moving target than Larry Niven’s 1964 short story “The Coldest Place.” Up to that point, astronomers widely believed that the planet Mercury was tidally locked to the Sun: its rotation matched that of its orbit and as a result, only one side ever faced the Sun, meaning that its dark side would have been much cooler. Niven took that bit of knowledge and incorporated it into his story his first and sent it off to Frederik Pohl’s ....

Saint Helena , Le Chevalier , Provence Alpes Côd Azur , United States , Ben Bova , James Baron , Clark Ashton Smith , Atlantic Ocean , Albert Einstein , Hal Clement Iceworld , Edmond Halley , Charles Stross , George Griffith , Urbain Le Verrier , Homer Eon Flint , Ray Cummings , Nebo Nabu , Isaac Asimov , Danny Boyle , John Munro , Saito Yamagata , Kurt Vonnegut , David Langford , Jo Marchant , Alane Nourse Brightside , Giovanni Zupi ,

AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO ? (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER


AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO - (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
1
AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal.
Patients with early-stage lung cancer are treated with the intention of cure; however, many relapse because treatment is limited to surgery and adjuvant chemotherapy.
2
Unprecedented clinical trial data show that osimertinib, the first approved targeted oral therapy in this setting, can reduce the risk of disease recurrence or death by 80% in patients with early-stage (IB-IIIA) EGFR mutation-positive NSCLC versus placebo. ....

United Kingdom , United States , Great Britain , Alex Larkinson , Karun Krishna , Carles Escriu , Le Chevalier , Collaborative Group , National Lung Cancer Audit , Clatterbridge Cancer Centre , Arch Pathol Lab , Royal College Of Physicians , Data Monitoring Committee , Regulatory Agency , National Institute For Health , Cancer Research United Kingdom , Foundation Trust In Liverpool , Project Orbis , National Institute , Care Excellence , Thoracic Medical Oncology , Astrazeneca United Kingdom , South America , Independent Data Monitoring Committee , Renal Metabolism , Adjuvant Cisplatin Evaluation ,